Vivomos

Vivo-MOrpholino (Vivo-MO) treatments were performed as previously described with slight modifications (Konantz and Antos, 2014; Wehner et al., 2017) . Briefly, custom-designed Vivo-MOs (Gene Tools) were dissolved in PBS at a concentration of 0.5 mM. Vivo-MOs were incubated for 5 min at 65 C prior preparation of the injection mix containing 0.475 mM Vivo-MO and 0.125 mg/ml fluorescently-labelled dextran (3000 MW; Thermo-Fisher Scientific #D3305, Thermo-Fisher Scientific #D3329). Approximately a total of 10 nl injection mix (10 repetitive injections of 1 nl each) was microinjected into the pericardial vein of 3 dpf larvae immediately before lesion. Larvae that showed strong and ubiquitous fluorescence at 2-3 h post-injection were subsequently lesioned. Sequences of translation blocking Vivo-MOs used are as follows. cthrc1a Vivo-MO 1: 5'-GTACCCATCATTACCGAAATGCAGT-3', cthrc1a Vivo-MO 2: 5'-CAGTTAGTTTGGTCGCTCCTGCTCT-3', cthrc1a Vivo-MO 3: 5'-TCTGCTGCCAACCAACTGTTTCTTA-3', tnfaip6 Vivo-MO: 5'-TCAGTCCGCAGTGGCTCATACAG-3'. cthrc1a MO 2 and cthrc1a MO 3 have recently been established in zebrafish (Cheng et al., 2019) . As control, a standard Vivo-MO from Gene Tools targeting a mutated splice site of human b-globin was used: 5'-CCTCTTACCTCAGTTACAATTTATA-3'.